RxDoctor Payments Data

Arvin Abueg, MD

Family Medicine · Canton, MONPI 1770814014

Payments from drug & device makers

$3,283in general payments, 2019–2025

Across 184 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$853
  • AstraZeneca$644
  • Amgen$301
  • Verona Pharma, Inc.$268
  • Lilly USA, LLC$232
  • Bayer$192
  • plus $792 from 13 others

What the payments were for

  • Food & beverage$3,283100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,283 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$6,347
Medicare patients
161
Services billed
317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide212$209,745
TrulicityDulaglutide85$96,222
EliquisApixaban107$93,071
Breztri AerosphereBudesonide/Glycopyr/Formoterol108$76,038
XareltoRivaroxaban97$74,083
VraylarCariprazine Hcl49$70,059
FarxigaDapagliflozin Propanediol62$51,134
MounjaroTirzepatide29$36,679
RybelsusSemaglutide30$34,150
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen858$32,421
OxycontinOxycodone Hcl27$25,481
Aimovig AutoinjectorErenumab-Aooe31$23,493
JanuviaSitagliptin Phosphate27$18,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,163
Incruse ElliptaUmeclidinium Bromide36$16,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$97$243,895242 claims
Lilly USA, LLCTrulicity, Mounjaro$232$132,901114 claims
AstraZenecaBreztri Aerosphere, Farxiga, Bevespi Aerosphere$644$131,844181 claims
PfizerEliquis$60$93,071107 claims
AbbVieVraylar, Linzess$853$79,02066 claims
BayerKerendia$192$14,84312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Canton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →